1. Home
  2. IQ vs CTMX Comparison

IQ vs CTMX Comparison

Compare IQ & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IQ

iQIYI Inc.

HOLD

Current Price

$1.01

Market Cap

872.3M

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$2.78

Market Cap

716.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IQ
CTMX
Founded
2009
2008
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.3M
716.9M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
IQ
CTMX
Price
$1.01
$2.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$2.91
$12.10
AVG Volume (30 Days)
9.0M
3.6M
Earning Date
05-18-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
$0.28
N/A
Revenue Next Year
$3.54
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$1.98
52 Week High
$2.72
$8.21

Technical Indicators

Market Signals
Indicator
IQ
CTMX
Relative Strength Index (RSI) 47.53 33.01
Support Level $0.99 N/A
Resistance Level $1.23 $3.93
Average True Range (ATR) 0.07 0.22
MACD 0.02 -0.09
Stochastic Oscillator 49.98 6.97

Price Performance

Historical Comparison
IQ
CTMX

About IQ iQIYI Inc.

Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: